A breakthrough experimental drug has shown promising results in shrinking advanced prostate cancer tumours, offering new hope ...

Nuvalent's NVL-655 and Zidesamtinib show strong potential as first-line therapies for NSCLC. Click here to find out why I ...

Professor Markus Sauer from the Biocentre of Julius-Maximilians-Universität (JMU) Würzburg in Bavaria, Germany ...

GLP-1 drugs, widely used for treating metabolic disorders, often face issues with long term tolerability, leading to side effects such as sarcopenia and bone density loss. These complications ...

Research suggests a new drug slowed the growth of prostate cancer cells, including those with a resistance to the hormone ...

New treatments like dotinurad provide safer, more effective solutions for millions battling gout and hyperuricemia.

A breakthrough in prostate cancer treatment has seen a drug shrink tumours in advanced disease ...

New Gene Therapy Approach Shows Promise for Duchenne Muscular Dystrophy July 24, 2024 — Researchers have made a significant breakthrough in developing a new gene therapy approach that restores ...

The FDA has granted BTD to GSK’22, a B7-H3-targeted antibody-drug conjugate, for the treatment of adult patients with ...

Biologics License Application acceptance supported by results from the Phase 3 Vivacity-MG3 study Results demonstrate sustained disease control over 24 weeks in a broad ...

Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced a significant milestone for its proprietary Nectin-4 targeted ADC (9MW2821). On January 8, 2025, ...